China developed a leukemia drug

With the interference of environmental pollution and other factors, the number of leukemias is increasing, and even spread to children with weak immune systems.

However, Chinese researchers have made great progress in research on leukemia suppression.

Researchers at the Strong Magnetic Field Science Center of the Chinese Academy of Sciences have recently developed a new type of leukemia inhibitor, CHMFL-074. Currently, in preclinical animal model experiments, the tumor inhibition rate in mice is 65%. Relevant academic achievements will be published in the international oncology academic journal Oncotarget.

According to reports, CHMFL-074 is a BCR-ABL small molecule targeted inhibitor against chronic myeloid leukemia (CML), which can effectively inhibit the proliferation of white blood cells in BCR-ABL-positive leukemia cell lines and primary chronic myeloid leukemia patients.

At present, the listed kinase inhibitor against BCR-ABL is mainly imatinib, which has become the first-line treatment for CML, but imatinib is susceptible to drug resistance and expensive to import, so many patients miss the best. Treatment timing.

Finally, the simple science of chronic myeloid leukemia, this type of leukemia is a malignant tumor formed by the clonal proliferation of bone marrow hematopoietic stem cells, characterized by myeloid myeloid hyperplasia, peripheral blood leukocytosis and splenomegaly. 15% of leukemia.

Studies have shown that abnormal expression and mutation of BCR-ABL fusion gene plays a key role in the occurrence, development and prognosis of chronic myeloid leukemia. BCR-ABL kinase is also a clinically proven target for the effective drug treatment of CML.